It sounds like anti-vaxx propaganda, but it is the case that Sweden has halted the use of SpikeVax for young people [under 30] due to complications (myocarditis and pericarditis). Similarly, in Denmark and Norway only Comirnaty is given to teens, and is recommended for young males up to 30.
The CDC has not noted such an advantage of Pfizer over Moderna in the case of these complications; it seems that Johnson & Johnson is the way to go for that age group (though their European analogue doesn't see it that way).
This week the state stopped reporting daily numbers, even though cases were up a fifth of a percentage point last Friday. (Apparently the MDPH is suffering from COVID fatigue.)
Friday, October 08, 2021
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment